PBK (TOPK) AntibodyRabbit Monoclonal Antibody

BACKGROUND

A novel mitotic kinase, PDZ-binding kinase or PBK, which is upregulated in a variety of neoplasms including hematological malignancies, has been the focus of attention with a goal to understand its role in malignant conversion and to examine as a possible new therapeutic target in disparate types of cancer. Studies provide a plausible explanation for the role of PBK augmenting tumor cell growth following transient appearance in different types of progenitor cells in vivo (1). PBK is a newly identified member of a novel MEK3/6-related MAPKK that may be enrolled in the activation of lymphoid cells and support testicular functions (2). In vitro, PBK binds specifically to PDZ2 of hDlg through its C-terminal T/SXV motif. PBK and hDlg are phosphorylated at mitosis in HeLa cells, and the mitotic phosphorylation of PBK is required for its kinase activity. In vitro, cdc2/cyclin B phosphorylates PBK. This evidence shows how PBK could link hDlg or other PDZ-containing proteins to signal transduction pathways regulating the cell cycle or cellular proliferation (3).

REFERENCES

1. Nandi AK, et al. Biochem Biophys Res Commun 358(1): 181-1 (2007)
2. Abe Y, et al. J Biol Chem 275(28):21525-31 (2000)
3. Gaudet S, et al. Proc Natl Acad Sci 97(10):5167-72 (2000)